Stock Detail
GENZYME CORPORATION - GENZYME CORPORATION
Biotechnology
GENZ @ Yahoo Finance | GENZ Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $75.66 | $75.70 | $0.00 | 0.00% | 0.00 | $75.66 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $75.62 | $75.62 | 2.81M | 19.76B | 4.69M | 47.86 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 75.74 | 75.70 | 75.66 | 75.62 | 75.58 |
Stock Profile
Genzyme Corporation operates as a biotechnology company. Its products and services focuses on rare genetic disorders, renal disease, kidney disease, cancer, orthopaedics, organ transplant, and diagnostic and predictive testing. The company operates in five segments: Renal, Therapeutics, Transplant, Biosurgery, and Diagnostics/Genetics. The Renal unit develops, manufactures, and distributes products that treat patients suffering from renal diseases, including chronic renal failure. The Therapeutics unit offers therapeutic products for genetic diseases; and other chronic debilitating diseases, including lysosomal storage disorders and other specialty therapeutics. The Transplant unit provides therapeutic products that address pretransplantation, prevention, and treatment of acute rejection in organ transplantation, as well as other auto-immune disorders. The Biosurgery unit develops, manufactures, and distributes biotherapeutics and biomaterial products, with an emphasis on products that meet medical needs in orthopaedics and broader surgical areas. The Diagnostics/Genetics unit offers vitro diagnostic products; and testing services for the oncology, and prenatal and reproductive markets. The company offers its products primarily to physicians, hospitals, and treatment centers in various countries, including the United States, the United Kingdom, Ireland, the Netherlands, Belgium, France, Canada, Switzerland, and Germany. Genzyme Corp. has an agreement with RenaMed Biologics, Inc. to jointly develop and commercialize RenaMed's Bio-Replacement Therapy for the treatment of acute renal failure; a collaboration with De Novo Pharmaceuticals, Ltd. to apply De Novo's molecular structure generating technology to focus on a disease target of interest to Genzyme; and a collaboration agreement with Epiontis GmbH to develop quality control tests for Genzyme's cartilage repair product Carticel. The company was founded in 1981 and is based in Cambridge, Massachusetts.